 DUBLIN, Ireland and KING OF PRUSSIA, Pa., March 01, 2021 GLOBE NEWSWIRE -- Nabriva Therapeutics plc NASDAQ: NBRV, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entered into a definitive agreement with certain healthcare-focused and institutional investors for the purchase and sale of i an aggregate of 10,361,010 ordinary shares or pre-funded warrants in lieu thereof and ii warrants to purchase up to an aggregate of 5,180,505 ordinary shares in a registered direct offering priced at-the-market under Nasdaq rules. Each ordinary share and accompanying warrant are being sold together at a combined purchase price of 2.4525, and each pre-funded warrant and accompanying warrant are being sold together at a combined purchase price of 2.4425. The warrants have an exercise price of 2.39 per share, are exercisable on the issuance date and will expire on the five-year anniversary of the issuance date. 